Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

GlobalData, the industry analysis specialist, has released its new report, "Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics market. The report identifies the key trends shaping and driving the global Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics market. Its scope includes -

• Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2018.
• Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
• Analysis of the current and future competition in the seven key countries Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics market.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics market.
• Analysis of key recent licensing and partnership agreements in Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What's the next big thing in the global Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics market landscape? - Identify, understand and capitalize.
   

More Info

The CAD Therapeutics Market is Forecast to Show Slow Growth until 2018

GlobalData’s analysis shows that the global Atherosclerosis or Coronary Artery Disease (CAD) therapeutics market stood at $12.0 billion in 2005 and grew at a Compound Annual Growth Rate (CAGR) of 3.8% to reach $14.5 billion in 2010. GlobalData forecasts that the global CAD therapeutics market will grow at a CAGR of 2.1% over the next eight years to reach $17.1 billion by 2018. The current CAD therapeutics market consists of drugs from various therapeutic classes such as statins, Angiotensin-Converting Enzyme (ACE) inhibitors, Beta Blockers (BBs), antiplatelets, Calcium Channel Blockers (CCBs) and nitrates. The current treatment options for CAD mainly include drugs such as Lipitor (atorvastatin calcium), Crestor (rosuvastatin calcium), Angiomax (bivalirudin), Plavix (clopidogrel bisulfate), Norvasc (amlodipine) and Altace (ramipril). The market is expected to show slow growth primarily due to the genericization of key market drugs during the forecast period, which will off-set the effects of the growing prevalence of the disease for the CAD therapeutics market. An increase in the prevalence of CAD is expected in the forecast period, mainly due to increasingly sedentary lifestyles, obesity, hypertension, dyslipidemia, reduction in High Density Lipoprotein Cholesterol (HDL-C) and a high cholesterol diet. The market is set to witness the patent expiration of various drugs, such as Plavix, which went off patent in the EU in 2009 and will lose its US patent in 2012. Lipitor lost its patent in November 2011 in the US and will lose it in 2012 in the EU. Angiomax is set to lose its patent in 2010 in the US and 2015 in the EU.  Crestor will lose its patent in 2016 in the US and the EU. These patent expiries will have an impact on the CAD therapeutics market during the forecast period and patients will have access to treatment for CAD at lower prices, reflecting brand erosion of these drugs. However, the expected launch of novel first-in-class (FIC) molecules present in the late stage pipeline and the growing prevalence of the disease will drive the CAD therapeutics market in the coming years.

Current Competition in the CAD Therapeutics Market is Strong

GlobalData found that the current competition in the CAD therapeutics market is strong due to the availability of a wide range of treatment options. The current CAD therapeutics market is well served, with drugs from various therapeutics classes such as statins, CCBs, BBs and nitrates. These drugs are cost effective and most widely prescribed in combination with ACE inhibitors. The presence of other combination products in the market, coupled with the effect of the impending genericization detailed above, will set the scene for a market share war until the launch of new products with high efficacy and safety profiles.

Strong Pipeline Will Drive the Atherosclerosis or CAD Therapeutics Market During the Forecast Period

GlobalData’s research indicates that the CAD pipeline is strong, with 76 molecules in various phases of clinical development. Out of these molecules, 18 are present in Phase III of clinical development process. Most of the molecules in the pipeline are classified as FIC. Out of 76 molecules present in the pipeline, 53 molecules are First-In-Class (FIC), eight are me-too molecules and four are product extensions in various phases of clinical development. Out of 18 molecules present in phase III, the FIC molecules are Anacetrapib, Dalcetrapib, Darapladib, Vorapaxar, Aliskiren, Mipomersen, Generx, Otamixaban and Varespladib. The strong CAD therapeutics pipeline indicates that in the future, the CAD therapeutics market will witness the launch of various molecules with novel disease-modifying modes of action.

Significant Unmet Need Provides Scope for New Entrants

According to the AHA (2010) update, CAD is the cause of about one in every six deaths in the US. In 2010 it was estimated that 78,500 Americans had a new heart attack and around 470,000 had cases of recurrent heart attacks, mostly due to CAD. In the CAD therapeutics market, there is a significant unmet need due to adverse reactions and safety issues related to drugs such as an increased bleeding tendency.This need can be addressed in the future by drugs that have greater efficacy and safety, with a novel mechanism of action and able to prevent secondary cardiovascular events such as Acute Coronary Syndrome (ACS), angina pectoris, stroke or heart attack. The CAD therapeutics market also needs drugs which can increase HDL-C and reduce LDL-C, with minimum side effects and increased efficacy.

1 Table of Contents
1 Table of Contents 3

    1.1 List of Tables 5
    1.2 List of Figures 6

2 Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics - Introduction 7

    2.1 Overview 7
    2.2 Types of Atherosclerosis 7
    2.3 Epidemiology 8
    2.4 Etiology 9
        2.4.1 Cells and Lipids 9
        2.4.2 ECM (Extracellular Matrix) 9
        2.4.3 Endothelial Injury as the Mechanism of Atherosclerosis 9
        2.4.4 Role of Low-Density Lipoprotein-Oxidative Stress 9
        2.4.5 Risk Factors 10
    2.5 Symptoms 11
    2.6 Diagnosis 12
    2.7 Pathophysiology 14
        2.7.1 Pathological Pathway for Atherosclerosis 15
    2.8 Treatment and Management Pattern 15
        2.8.1 HMG-CoA Reductase Inhibitors 15
        2.8.2 ACE Inhibitors 15
        2.8.3 Beta Blockers 16
        2.8.4 Omega-3 Fatty Acids 16
        2.8.5 Aldosterone Antagonists 16
        2.8.6 Calcium Channel Blockers 16
        2.8.7 Nicotinic Acid Derivatives 16
        2.8.8 Fibric Acid Derivatives 16
        2.8.9 Platelet Aggregation Inhibitors 16
        2.8.10 Therapeutic Lifestyle Changes (TLC) 16
    2.9 GlobalData Pipeline Report Guidance 19

3 Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics - Market Characterization 20

    3.1 Atherosclerosis or CAD Therapeutics Market Size (2005-2010) - Global 20
    3.2 Atherosclerosis or CAD Therapeutics Market Forecast (2010-2018) - Global 21
    3.3 Atherosclerosis or CAD Therapeutics Market - The US (2005-2010) 22
    3.4 Atherosclerosis or CAD Therapeutics Market Forecast - The US (2010-2018) 23
    3.5 Atherosclerosis or CAD Therapeutics Market - France (2005-2010) 24
    3.6 Atherosclerosis or CAD Therapeutics Market Forecast - France (2010-2018) 25
    3.7 Atherosclerosis or CAD Therapeutics Market - Germany (2005-2010) 26
    3.8 Atherosclerosis or CAD Therapeutics Market Forecast - Germany (2010-2018) 27
    3.9 Atherosclerosis or CAD Therapeutics Market - Italy (2005-2010) 28
    3.10 Atherosclerosis or CAD Therapeutics Market Forecast - Italy (2010-2018) 29
    3.11 Atherosclerosis or CAD Therapeutics Market - Spain (2005-2010) 30
    3.12 Atherosclerosis or CAD Therapeutics Market Forecast - Spain (2010-2018) 31
    3.13 Atherosclerosis or CAD Therapeutics Market - The UK (2005-2010) 32
    3.14 Atherosclerosis or CAD Therapeutics Market Forecast - The UK (2010-2018) 33
    3.15 Atherosclerosis or CAD Therapeutics Market - Japan (2005-2010) 34
    3.16 Atherosclerosis or CAD Therapeutics Market Forecast - Japan (2010-2018) 35
    3.17 Drivers and Barriers for the Atherosclerosis or CAD Therapeutics Market 36
        3.17.1 Atherosclerosis or CAD Therapeutics Market Drivers 36
        3.17.2 Atherosclerosis or CAD Therapeutics Market Barriers 36
    3.18 Opportunity and Unmet Need 37
    3.19 Key Takeaway 38

4 Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics - Competitive Assessment 39

    4.1 Overview 39
    4.2 Strategic Competitor Assessment 39
    4.3 Product Profile for the Major Products in Atherosclerosis or CAD Market 40
        4.3.1 Lipitor (atorvastatin calcium) 40
        4.3.2 Crestor (rosuvastatin calcium) 42
        4.3.3 Plavix (clopidogrel bisulfate) 43
        4.3.4 Altace (ramipril) 44
        4.3.5 Norvasc (amlodipine) 45
        4.3.6 Niaspan (nicotinic acid) 46
    4.4 Key Takeaway 47

5 Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics - Pipeline Assessment 48

    5.1 Overview 48
    5.2 Strategic Pipeline Assessment 48
    5.3 Atherosclerosis or CAD Therapeutics Market - Pipeline Assessment by Phase of Development 48
        5.3.1 Atherosclerosis or CAD Therapeutics - Phase III Pipeline 48
        5.3.2 Atherosclerosis or CAD Therapeutics - Phase II Pipeline 49
        5.3.3 Atherosclerosis or CAD Therapeutics - Phase I Clinical Pipeline 50
        5.3.4 Atherosclerosis or CAD Therapeutics - Preclinical Pipeline 50
        5.3.5 Atherosclerosis or CAD Therapeutics - Discovery Pipeline 51
    5.4 Atherosclerosis or CAD Therapeutics - Pipeline by Mechanism of Action 51
    5.5 Technology Trends Analytical Framework 53
    5.6 Atherosclerosis or CAD Therapeutics Market - Most Promising Drugs under Clinical Development 54
    5.7 Most Promising Drug Profiles 55
        5.7.1 Anacetrapib (MK- 0859) 55
        5.7.2 Darapladib 56
        5.7.3 Dalcetrapib (RG1658) 57
        5.7.4 Mipomersen 58
        5.7.5 Varespladib (A-002) 59
        5.7.6 MK-0524B 60
        5.7.7 Aleglitazar (RG1439) 61
        5.7.8 Vorapaxar 62
        5.7.9 Aliskiren 63
        5.7.10 Canakinumab (ACZ885) 64
        5.7.11 Generx 64
        5.7.12 Cangrelor 65
        5.7.13 Otamixaban 66
        5.7.14 Xarelto (rivaroxaban) 67
    5.8 Key Takeaway 68

6 Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics - Clinical Trials Mapping 69

    6.1 Clinical Trials by Region/Country (The US, EU5 and Japan) 69
    6.2 Clinical Trials by Phase of Clinical Development 70
    6.3 Clinical Trials by Trial Status 71
    6.4 Prominent Sponsors 72
    6.5 Brief Profiles of Top Ten Companies Participating in Therapeutics Clinical Trials 74

7 Coronary Artery Disease (CAD) Therapeutics - Strategic Assessment 75

    7.1 Key Events Impacting the Future Market 75
    7.2 Future Market Competition Scenario 76

8 Coronary Artery Disease (CAD) Therapeutics - Future Players 78

    8.1 Introduction 78
    8.2 Company Profiles 78
        8.2.1 GlaxoSmithKline Plc 78
        8.2.2 Merck & Co., Inc. 80
        8.2.3 F Hoffmann La Roche 82
        8.2.4 ISIS Pharmaceuticals 82
        8.2.5 Anthera Pharmaceuticals 83
        8.2.6 Novartis A G 84
        8.2.7 Sanofi 85
        8.2.8 Johnson & Johnson 86
        8.2.9 Bayer AG 87
        8.2.10 Cardium Therapeutics 88
        8.2.11 The Medicines Company 90
        8.2.12 Tabular Presentation Details of Other Companies in the Pipeline 91
        8.2.13 Key Takeaway 97

9 Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics - Licensing & Partnership Deals 98

10 Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics - Appendix 103

    10.1 Market Definitions 103
    10.2 Acronyms 103
    10.3 Methodology 106
        10.3.1 Coverage 107
        10.3.2 Secondary Research 107
        10.3.3 Forecasting 107
        10.3.4 Primary Research 109
        10.3.5 Expert Panel Validation 110
    10.4 Contact Us 110
    10.5 Disclaimer 110
    10.6 Bibliography 111

List of Tables
1.1 List of Tables

    Table 1: Atherosclerosis or CAD Therapeutics - Modified AHA Consensus Classification Based on Morphologic Descriptions* 8
    Table 2: Atherosclerosis or CAD Therapeutics - NCEP ATP III Classification of Cholesterol and Triglyceride Levels 13
    Table 3: Atherosclerosis or CAD Therapeutics - ATP III LDL-C Goals and Outpoints for Therapeutics Lifestyle Changes and Drug Therapy in Different Risk Categories 17
    Table 4: Atherosclerosis or CAD Therapeutics Market, Global, Revenue ($bn), 2005-2010 20
    Table 5: Atherosclerosis or CAD Therapeutics Market, Global, Forecast ($bn), 2010-2018 21
    Table 6: Atherosclerosis or CAD Therapeutics Market, The US, Forecast ($bn), 2005-2010 22
    Table 7: Atherosclerosis or CAD Therapeutics Market, The US, Forecast ($bn), 2010-2018 23
    Table 8: Atherosclerosis or CAD Therapeutics Market, France, Revenue ($m), 2005-2010 24
    Table 9: Atherosclerosis or CAD Therapeutics Market, France, Forecast ($m), 2010-2018 25
    Table 10: Atherosclerosis or CAD Therapeutics Market, Germany, Revenue ($bn), 2005-2010 26
    Table 11: Atherosclerosis or CAD Therapeutics Market, Germany, Forecast ($bn), 2010-2018 27
    Table 12: Atherosclerosis or CAD Therapeutics Market, Italy, Revenue ($m), 2005-2010 28
    Table 13: Atherosclerosis or CAD Therapeutics Market, Italy, Forecast ($m), 2010-2018 29
    Table 14: Atherosclerosis or CAD Therapeutics Market, Spain, Revenue ($m), 2005-2010 30
    Table 15: Atherosclerosis or CAD Therapeutics Market, Spain, Forecast ($m), 2010-2018 31
    Table 16: Atherosclerosis or CAD Therapeutics Market, The UK, Revenue ($m), 2005-2010 32
    Table 17: Atherosclerosis or CAD Therapeutics Market, The UK, Forecast ($m), 2010-2018 33
    Table 18: Atherosclerosis or CAD Therapeutics Market, Japan, Revenue ($m), 2005-2010 34
    Table 19: Atherosclerosis or CAD Therapeutics Market, Japan, Forecast ($m), 2010-2018 35
    Table 20: Atherosclerosis or CAD Therapeutics - Phase III Pipeline, 2011 48
    Table 21: Atherosclerosis or CAD Therapeutics - Phase II Pipeline, 2011 49
    Table 22: Atherosclerosis or CAD Therapeutics - Phase I Pipeline, 2011 50
    Table 23: Atherosclerosis or CAD Therapeutics - Preclinical Pipeline, 2011 50
    Table 24: Atherosclerosis or CAD Therapeutics - Discovery Pipeline, 2011 51
    Table 25: Atherosclerosis or CAD Therapeutics - Most Promising Drugs Under Clinical Development, 2011 54
    Table 26: Atherosclerosis or CAD Therapeutics - Clinical Trials by Country, 2011 69
    Table 27: Atherosclerosis or CAD Therapeutics, Major Markets - Clinical Trials by Phase, 2011 70
    Table 28: Atherosclerosis or CAD Therapeutics, Major Markets, Clinical Trials by Development Status, 2011 71
    Table 29: Atherosclerosis or CAD Therapeutics, Major Markets, Overall Sponsors, 2011 72
    Table 30: Atherosclerosis or CAD Therapeutics, Major Markets, Prominent Sponsors, 2011 73
    Table 31: Atherosclerosis or CAD Therapeutics - Companies Participating in Clinical Trials, 2011 74
    Table 32: GlaxoSmithKline Pipeline Products 79
    Table 33: Merck Pipeline Products 81
    Table 34: Pipeline Products 83
    Table 35: Anthera Pharmaceuticals Company Pipeline Products 83
    Table 36: Novartis A G Company Pipeline Products 85
    Table 37: Sanofi - CAD Pipeline Products, 2011 86
    Table 38: Johnson and Johnson Company - CAD Pipeline Products, 2011 86
    Table 39: Bayer AG - CAD Pipeline Products, 2011 88
    Table 40: Cardium Therapeutics, Inc., Product pipeline 2011 89
    Table 41: Product pipeline 2011 91
    Table 42: Other Companies in Pipeline, CAD Therapeutics, 2011 91
    Table 43: CAD Therapeutics, Global, Deals, 2011 98

List of Figures
1.2 List of Figures

    Figure 1: Atherosclerosis or CAD Therapeutics - Endothelial Dysfunction 11
    Figure 2: Stages in Development of Atherosclerosis Lesion 14
    Figure 3: Atherosclerosis or CAD Therapeutics - Pathology 18
    Figure 4: Atherosclerosis or CAD Therapeutics Market, Global, Revenue ($bn), 2005-2010 20
    Figure 5: Atherosclerosis or CAD Therapeutics Market, Global, Forecast ($bn), 2010-2018 21
    Figure 6: Atherosclerosis or CAD Therapeutics Market, The US, Revenue ($bn), 2005-2010 22
    Figure 7: Atherosclerosis or CAD Therapeutics Market, The US, Forecast ($bn), 2010-2018 23
    Figure 8: Atherosclerosis or CAD Therapeutics Market, France, Revenue ($m), 2005-2010 24
    Figure 9: Atherosclerosis or CAD Therapeutics Market, France, Forecast ($m), 2010-2018 25
    Figure 10: Atherosclerosis or CAD Therapeutics Market, Germany, Revenue ($bn), 2005-2010 26
    Figure 11: Atherosclerosis or CAD Therapeutics Market, Germany, Forecast ($bn), 2010-2018 27
    Figure 12: Atherosclerosis or CAD Therapeutics Market, Italy, Revenue ($m), 2005-2010 28
    Figure 13: Atherosclerosis or CAD Therapeutics Market, Italy, Forecast ($m), 2010-2018 29
    Figure 14: Atherosclerosis or CAD Therapeutics Market, Spain, Revenue ($m), 2005-2010 30
    Figure 15: Atherosclerosis or CAD Therapeutics Market, Spain, Forecast ($m), 2010-2018 31
    Figure 16: Atherosclerosis or CAD Therapeutics Market, The UK, Revenue ($m), 2005-2010 32
    Figure 17: Atherosclerosis or CAD Therapeutics Market, The UK, Forecast ($m), 2010-2018 33
    Figure 18: Atherosclerosis or CAD Therapeutics Market, Japan, Revenue ($m), 2005-2010 34
    Figure 19: Atherosclerosis or CAD Therapeutics Market, Japan, Forecast ($m), 2010-2018 35
    Figure 20: Opportunity and Unmet Need in the Atherosclerosis or CAD Therapeutics Market, 2011 37
    Figure 21: Atherosclerosis or CAD Therapeutics - Strategic Competitor Assessment, 2011 40
    Figure 22: Atherosclerosis or CAD Therapeutics - Clinical Pipeline by Mechanism of Action, 2011 52
    Figure 23: Atherosclerosis or CAD Therapeutics Market - Pipeline by Phase of Development, 2011 52
    Figure 24: Atherosclerosis or CAD Therapeutics Market Technology Trends Analytics Framework, 2011 53
    Figure 25: Atherosclerosis or CAD Therapeutics - Technology Trends Analytics Framework - Description, 2011 54
    Figure 26: Atherosclerosis or CAD Therapeutics - Clinical Trials by Country, 2011 69
    Figure 27: Atherosclerosis or CAD Therapeutics, Major Markets - Clinical Trials by Phase, 2011 70
    Figure 28: Atherosclerosis or CAD Therapeutics, Major Markets, Clinical Trials by Development Status, 2011 71
    Figure 29: Atherosclerosis or CAD Therapeutics, Overall Sponsors, 2011 72
    Figure 30: Atherosclerosis or CAD Therapeutics, Major Markets, Prominent Sponsors (%), 2011 73
    Figure 31: Atherosclerosis or CAD Therapeutics, Clinical Trials of Top Ten Companies by Phase, 2011 74
    Figure 32: Atherosclerosis or CAD Therapeutics Market, Drivers and Barriers 2011 75
    Figure 33: Implications for Future Market Competition in the Atherosclerosis or CAD Therapeutics Market, 2011 76
    Figure 34: Atherosclerosis or CAD Therapeutics Market - Clinical Pipeline by Company, 2011 78
    Figure 35: GlobalData Market Forecasting Model 109